SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fitch Ratings assigns rating to Glenmark Pharmaceuticals' proposed US dollar-denominated notes

14 Jan 2020 Evaluate

Credit rating agency -- Fitch Ratings has assigned Glenmark Pharmaceuticals’ proposed US dollar-denominated senior unsecured notes ‘BB’ rating with a stable outlook. The rating indicates an elevated vulnerability to default risk, particularly in the event of adverse changes in business or economic conditions over time.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2360.70 -3.65 (-0.15%)
11-May-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.65
Dr. Reddys Lab 1287.90
Cipla 1341.95
Zydus Lifesciences 943.25
Lupin 2252.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×